Altre lingue ANGN BIOM

Azioni

ANGN

US03476J1079

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
8,99 ^USD	-1,21%		+7,02%	-10,10%

2023	Angion Biomedica Corp. annuncia le dimissioni di Assaf Segal dal suo Consiglio di Amministrazione	CI
2023	Angion Biomedia attuerà un frazionamento inverso 10 per 1	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Durable immunogenicity of ELI-002 2P in AMPLIFY-201: Lymph node targeted mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer	08/04
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting	05/04
Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates	29/03
Elicio Therapeutics Announces $6.0 Million Private Placement Financing	18/03
Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting	06/03
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors	25/01
Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference	16/01
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002	09/01
Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference	04/12
Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates	09/11
ANGN BIOM : Lymph Node Targeted AMP-peptide Vaccines Generate Functional T cell Immunity Against Mutant p53 and BRAF (SITC – Scientific Poster)	03/11
ANGN BIOM : ELI-002 Immunotherapy Induces Broad Polyfunctional T cell Responses in Subjects with High Relapse Risk KRAS Mutated Pancreatic Ductal Adenocarcinoma and Colorectal Cancer (SITC – Scientific Poster)	03/11
ANGN BIOM : Management Change - Form 8-K	12/10/23
Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting	11/10/23
Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer	27/09/23
Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines	07/09/23
Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference	06/09/23
Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer	05/09/23
Angion Biomedica Corp. Announces Resignation of Assaf Segal from Its Board of Directors	30/08/23
Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics	28/08/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue ANGN BIOM

Azioni

ANGN

US03476J1079

Altre lingue

Filtri